Testing the efficacy of a human full-length OPG-Fc analog in a severe model of cardiotoxin-induced skeletal muscle injury and repair

Testing the efficacy of a human full-length OPG-Fc analog in a severe model of cardiotoxin-induced skeletal muscle injury and repair

Although receptor-activator of nuclear factor κB (RANK), its ligand RANKL, and osteoprotegerin (OPG), which are members of the tumor necrosis factor (TNF) superfamily, were first discovered in bone cells, they are also expressed in other cells, including skeletal muscle. We previously showed that th...

Full description

Bibliographic Details
Main Authors: Zineb Bouredji, Dounia Hamoudi, Laetitia Marcadet, Anteneh Argaw, Jérôme Frenette
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
Osteoprotegerin
human full-length OPG-Fc
RANK/RANKL/OPG
muscle injury
muscle repair
protein-Fc therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050121000620

Internet

http://www.sciencedirect.com/science/article/pii/S2329050121000620

Similar Items